Rat tissue collagen modified by advanced glycation: Correlation with duration of diabetes and glycemic control

Clinical Chemistry and Laboratory Medicine

Volumn 37, Issue 8, 1999, Pages 813-820

  Turk, Zdenka ^a   Mišur, Irena ^a   Turk, Nikša ^a,b   Benko, Bojan ^c  

^a University of Zagreb   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c INSTITUTE OF IMMUNOLOGY   (Croatia)

Author keywords

Advanced glycation end products; Aortic collagen; Diabetes; ELISA; Tendon collagen

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINO ACID; COLLAGEN; COLLAGENASE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; PEPSIN A; PHLORIZIN; SCLEROPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; DIABETES MELLITUS; DIGESTION; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GLYCATION; HYPERGLYCEMIA; IMMUNOBLOTTING; IMMUNOCHEMISTRY; INSULIN TREATMENT; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RAT; TENDON; TIME; TURNOVER TIME;

ALLOXAN; ANIMALS; AORTA; BLOOD GLUCOSE; COLLAGEN; DIABETES MELLITUS, EXPERIMENTAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOSYLATION END PRODUCTS, ADVANCED; INSULIN; KIDNEY TUBULES; PHLORHIZIN; RATS; RATS, WISTAR; TENDONS;

ANIMALIA;

EID: 0344069719     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.1999.122     Document Type: Article

References (33)

1. Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and ageing. Lab Invest 1994; 70: 138-51.
2. Njoroge FG, Monnier VM. The chemistry of the Maillard reaction under physiological conditions: a review. In: Baynes JW, Monnier VM, editors. The Maillard reaction and aging, diabetes and nutrition. New York: AR Liss, 1989: 85-109.
3. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318:1315-21.
4. Reiser KM. Nonenzymatic glycation of collagen in aging and diabetes. Proc Soc Biol Med 1998; 218:23-37.
5. Sims TJ, Rasmussen LM, Oxlund H, Bailey AJ. The role of glycation cross-links in diabetic vascular stiffening. Diabetologia 1996; 39:946-51.
6. Sakata N, Meng J, Jimi S, Takebayashi S. Nonenzymatic glycation and extractability of collagen in human atherosclerotic plaques. Atherosclerosis 1995; 116:63-75.
7. Munch G, Keis R, Wessels A, Riederer P, Bahner U, Heidland A, et al. Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem 1997; 35: 669-77
8. Mitsuhashi T, Vlassara H, Founds HW, Li YM. Standardizing the immunological measurement of advanced glycation endproducts using normal human serum J Immunol Methods 1997; 207:79-88.
9. Sell DR, Lapolla A, Odetti P, Fogarty J, Monnier VM. Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM. Diabetes 1992; 41:1286-92.
10. Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product N sup epsilon-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 1997; 99:457-68.
11. Niwa T, Katsuzaki T, Miyazaki S, Miyazaki T, Ishizaki Y, Hayase F, et al. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J Clin Invest 1997; 99: 1272-80.
12. Miyata S, Monnier VM. Immunohistochemical detection of advanced glycosyloation endproducts in diabetic tissues using monoclonal antibody to pyrraline. J Clin Invest 1992; 89:1102-12.
13. Dorrian CA, Cathcart S, Clausen J, Shapiro D, Dominiczak MH. Factors in human serum interfere with the measurement of advanced glycation endproducts. Cell Molec Biol 1998; 44:1069-79.
14. Meng J, Sakata N, Takebayashi S, Asano T, Futata T, Araki N, et al. Advanced glycation end products of the Maillard reaction in aortic pepsin-insoluble and pepsin-soluble collagen from diabetic rats. Diabetes 1996; 45:1037-43.
15. Stegemann H, Stalder K. Determination of hydroxyproline. Clin Chim Acta 1967; 18:267-73.
16. Hodge JE, Rist CE. The Amadori rearrangement under new conditions and its significance for nonenzymatic browning reactions. J Am Chem Soc 1953; 75:316-22.
17. Bradford MM. A rapid and sensitive method for the quantities of protein utilising the principle of protein-dye binding. Anal Biochem 1976; 72:248-54.
18. Makita Z, Vlassara H, Cerami A, Bucala R. Immunochemical detection of advanced glycation end products in vivo. J Biol Chem 1992; 267:5133-8.
19. Ikeda K, Nagai R, Sakamoto T, Sano H, Araki T, Sakata N, et al. Immunochemical approaches to AGE-structures: characterization of anti-AGE antibodies. J Immunol Methods 1998; 215:95-104.
20. Odetti P, Traverse N, Cosso L, Noberasco G, Pronzato MA, Marinari UM. Good glycaemic control reduces oxidation and glycation end-products in collagen of diabetic rats. Diabetologia 1996; 39:1440-7.
21. Nakayama H, Mitsuhashi T, Kuwajima S, Aoki S, Kuroda Y, Itoh T. Immunochemical detection of advanced glycation end products in lens crystallins from streptozotocin-induced diabetic rats. Diabetes 1993; 42:345-50.
22. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991; 40:1328-34.
23. Miksik I, Deyl Z. Change in the amount of ε-hexosyllysine, UV absorbance, and fluorescence of collagen with age in different animal species. J Gerontol 1991; 46:B111-6.
24. Turk Z, Misur I, Turk N. Temporal association between lens protein glycation and cataract development in diabetic rats. Acta Diabetol 1997; 34:49-54.
25. Lyons TJ, Jenkins AJ. Glycation, oxidation, and lipoxidation in the development of the complications of diabetes: a carbonyl stress hypothesis. Diabetes Rev 1997; 5: 365-91.
26. Thornalley PJ. Advanced glycation and the development of diabetic complications. Unifying the involvement of glucose, methylglyoxal and oxidative stress. Endocrin Metabol 1996; 3:149-66.
27. Hanssen KF. Making sense of advanced glycation endproducts. International Diabetes Monitor 1998; 10:1-5.
28. Itakura M, Yoshikawa H, Bannai C, Kato M, Kunika K, Kawakarni Y, et al. Aminoguanidine decreases urinary albumin and high-molecular-weight proteins in diabetic rats. Life Sciences 1991; 49:889-97.
29. Stitt AW, Moore JE, Sharkey JA, Murphy G, Simpson DAC, Bucala R, et al. Advanced glycation end products in vitreous: structural and functional implications for diabetic vitreopathy. Invest Ophthal & Vis Sci 1998; 39:2517-23.
30. Sajithlal GB, Chithra P, Chandrakasan G. Advanced glycation end products induce crosslinking of collagen in vitro. Biochim Biophys Acta 1998; 1407:215-24.
31. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-86.
32. Lyons TJ, Bailie KE, Dyer DG, Dunn JA, Baynes JW. Decrease in skin collagen glycation with improved glycaemic control in patients with insulin-dependent diabetes mellitus. J Clin Invest 1991; 87:1910-5.
33. Salmela PI, Oikarinen Al, Ukkola O, Karjalainen A, Linnaluoto M, Puukka R. Improved metabolic control in patients with non-insulin-dependent diabetes mellitus is associated with a slower accumulation of glycation products in collagen. Eur J Clin Invest 1995; 25:494-500.